Table of Contents
Chapter 1. Global Neuropathic Pain Market Executive Summary
1.1. Global Neuropathic Pain Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Class
1.3.2. By Indication
1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Neuropathic Pain Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Neuropathic Pain Market Dynamics
3.1. Market Drivers
3.1.1. Rise in Cases of Spinal Stenosis and Diabetic Neuropathy
3.1.2. Increase in Prevalence of Chronic Diseases
3.1.3. Growing Geriatric Population
3.2. Market Challenges
3.2.1. High Cost of Drug Development
3.2.2. Stringent Regulatory Approvals
3.3. Market Opportunities
3.3.1. Advances in Drug Development Technologies
3.3.2. Expansion in Emerging Markets
3.3.3. Rising Investments in Research and Development
Chapter 4. Global Neuropathic Pain Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Neuropathic Pain Market Size & Forecasts by Drug Class 2022-2032
5.1. Segment Dashboard
5.2. Global Neuropathic Pain Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Antidepressants
5.2.1.1. Tricyclic Antidepressants
5.2.1.2. Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
5.2.2. Anticonvulsant
5.2.3. Opioids
5.2.4. Capsaicin
5.2.5. Others
Chapter 6. Global Neuropathic Pain Market Size & Forecasts by Indication 2022-2032
6.1. Segment Dashboard
6.2. Global Neuropathic Pain Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Diabetic Neuropathy
6.2.2. Spinal Stenosis
6.2.3. Chemotherapy-Induced Peripheral Neuropathy
6.2.4. Others
Chapter 7. Global Neuropathic Pain Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Segment Dashboard
7.2. Global Neuropathic Pain Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Hospital Pharmacies
7.2.2. Drugs Stores and Retail Pharmacies
7.2.3. Online Pharmacies
Chapter 8. Global Neuropathic Pain Market Size & Forecasts by Region 2022-2032
8.1. North America Neuropathic Pain Market
8.1.1. U.S. Neuropathic Pain Market
8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
8.1.1.2. Indication breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Neuropathic Pain Market
8.2. Europe Neuropathic Pain Market
8.2.1. Germany Neuropathic Pain Market
8.2.2. UK Neuropathic Pain Market
8.2.3. France Neuropathic Pain Market
8.2.4. Italy Neuropathic Pain Market
8.2.5. Spain Neuropathic Pain Market
8.2.6. Rest of Europe Neuropathic Pain Market
8.3. Asia-Pacific Neuropathic Pain Market
8.3.1. China Neuropathic Pain Market
8.3.2. Japan Neuropathic Pain Market
8.3.3. Australia Neuropathic Pain Market
8.3.4. India Neuropathic Pain Market
8.3.5. South Korea Neuropathic Pain Market
8.3.6. Rest of Asia Pacific Neuropathic Pain Market
8.4. Latin America Neuropathic Pain Market
8.4.1. Brazil Neuropathic Pain Market
8.4.2. Mexico Neuropathic Pain Market
8.4.2. Rest of Latin America Neuropathic Pain Market
8.5. Middle East & Africa Neuropathic Pain Market
8.5.1. Saudi Arabia Neuropathic Pain Market
8.5.2. South Africa Neuropathic Pain Market
8.5.3. Rest of Middle East & Africa Neuropathic Pain Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Abbott Laboratories
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Collegium Pharmaceutical, Inc.
9.3.3. Eli Lilly and Company
9.3.4. Glenmark Pharmaceuticals Limited
9.3.5. Grunenthal
9.3.6. Mallinckrodt Pharmaceuticals
9.3.7. Novartis AG
9.3.8. Pfizer Inc.
9.3.9. Sun Pharmaceutical Industries Ltd.
9.3.10. Teva Pharmaceutical Industries Ltd.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes